157 related articles for article (PubMed ID: 12846768)
1. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab.
ter Meulen CG; Göertz JH; Klasen IS; Verweij CM; Hilbrands LB; Wetzels JF; Hoitsma AJ
Kidney Int; 2003 Aug; 64(2):697-703. PubMed ID: 12846768
[TBL] [Abstract][Full Text] [Related]
2. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
3. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
5. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
6. An assessment of serum and urine soluble interleukin-2 receptor concentrations during renal transplant rejection.
Bock GH; Neu L; Long C; Patterson LT; Korb S; Gelpi J; Nelson DL
Am J Kidney Dis; 1994 Mar; 23(3):421-6. PubMed ID: 8128944
[TBL] [Abstract][Full Text] [Related]
7. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
9. Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period.
Zivčić-Ćosić S; Lisjak J; Rački S; Trobonjača Z
Int Urol Nephrol; 2014 Jan; 46(1):191-200. PubMed ID: 23515930
[TBL] [Abstract][Full Text] [Related]
10. Impaired urinary excretion of soluble IL-2 receptors in patients with systemic lupus erythematosus and rheumatoid arthritis.
Manoussakis MN; Germanidis GS; Drosos AA; Moutsopoulos HM
Lupus; 1992 Feb; 1(2):105-9. PubMed ID: 1301961
[TBL] [Abstract][Full Text] [Related]
11. Strong inflammatory cytokine response in male and strong anti-inflammatory response in female kidney transplant recipients with urinary tract infection.
Sadeghi M; Daniel V; Naujokat C; Wiesel M; Hergesell O; Opelz G
Transpl Int; 2005 Feb; 18(2):177-85. PubMed ID: 15691270
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab in treatment of multiple sclerosis patients.
Ali EN; Healy BC; Stazzone LA; Brown BA; Weiner HL; Khoury SJ
Mult Scler; 2009 Feb; 15(2):272-4. PubMed ID: 19136546
[TBL] [Abstract][Full Text] [Related]
14. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclosporine A on serum and urinary soluble interleukin-2 receptor in patients with lupus nephritis.
Tang Z; Zhang J; Zhang S; Li L
Chin Med J (Engl); 1997 Sep; 110(9):686-9. PubMed ID: 9642325
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.
Goebel J; Stevens E; Forrest K; Roszman TL
Transpl Immunol; 2000 Nov; 8(3):153-9. PubMed ID: 11147695
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
Busse WW; Israel E; Nelson HS; Baker JW; Charous BL; Young DY; Vexler V; Shames RS;
Am J Respir Crit Care Med; 2008 Nov; 178(10):1002-8. PubMed ID: 18787222
[TBL] [Abstract][Full Text] [Related]
18. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
Schroeder TJ; Helling T; McKenna RM; Rush D; Jeffrey JR; Brewer B; Martin LA; Traylor D; Fisher RA; First MR
Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082
[TBL] [Abstract][Full Text] [Related]
19. Strikingly higher interleukin (IL)-1alpha, IL-1beta and soluble interleukin-1 receptor antagonist (sIL-1RA) but similar IL-2, sIL-2R, IL-3, IL-4, IL-6, sIL-6R, IL-10, tumour necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta and interferon IFN-gamma urine levels in healthy females compared to healthy males: protection against urinary tract injury?
Sadeghi M; Daniel V; Naujokat C; Weimer R; Opelz G
Clin Exp Immunol; 2005 Nov; 142(2):312-7. PubMed ID: 16232218
[TBL] [Abstract][Full Text] [Related]
20. Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.
Bock GH; Ongkingco JR; Patterson LT; Ruley J; Schroepfer LR; Nelson DL
Pediatr Nephrol; 1993 Oct; 7(5):523-8. PubMed ID: 8251314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
